Drug
Lamivudine clinical trials
Also written Epivir, 3TC and Zeffix.
Counted the way a researcher would: Lamivudine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Lamivudine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Lamivudine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Nov 1995 · EPIVIR · NDA 020564 (FDA, Drugs@FDA)
- European Union
- 8 Aug 1996 · Epivir · EMEA/H/C/000107 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
199 studies that test it; most in 2015 (15)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 1 |
| 1999 | 10 |
| 2000 | 5 |
| 2001 | 4 |
| 2002 | 8 |
| 2003 | 7 |
| 2004 | 10 |
| 2005 | 11 |
| 2006 | 8 |
| 2007 | 9 |
| 2008 | 7 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 8 |
| 2015 | 15 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 7 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 76 · Other 163
National Institute of Allergy and Infectious Diseases (NIAID) (33) · ViiV Healthcare (18) · Glaxo Wellcome (12) · Merck Sharp & Dohme LLC (10) · Bristol-Myers Squibb (7) · ANRS, Emerging Infectious Diseases (6) · GlaxoSmithKline (5) · Fundación Huésped (4)
Often tested with
Tested in the same studies.
Zidovudine (68) · Dolutegravir (37) · Tenofovir (36) · Abacavir (32) · Efavirenz (32) · Nevirapine (23) · Stavudine (23) · Ritonavir (19)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Lamivudine is the comparator. A study of two new drugs counts under both.
- 1Dolutegravir · Johns Hopkins University · next primary completion Jan 2028
- 1Dolutegravir Sodium/Lamivudine · Johns Hopkins University · next primary completion Jan 2028
Reaching primary completion within a year · 4
Studies that test Lamivudine.
- Dec 2026Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperiencePhase 4 · Instituto Mexicano del Seguro Social
- Jun 2027Lamivudine as a Novel Clinical Effort for Rett SyndromePhase 2 · Maria Denise Fernandes Carvalho de Andrade
- Jun 2027A Study of Exercise and Pharmacologic Intervention on Systemic InflammationPhase 1 · Icahn School of Medicine at Mount Sinai
- Jul 2027Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerPhase 2 · Roswell Park Cancer Institute
Studies
Open first, then newest update. How each study uses Lamivudine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 239
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingPhase 3ViiV HealthcareNCT07393659Written as Dolutegravir (DTG)/ Lamivudine (3TC)
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)RecruitingPhase 2Merck Sharp & Dohme LLCNCT04375800Written as DOR/3TC/TDF
- Efficacy and Safety of Doravirine in the Rapid InitiationRecruitingPhase 4Fundación HuéspedNCT07357584Written as Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Lamivudine (3TC)
- DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionRecruitingPhase 3ANRS, Emerging Infectious DiseasesNCT06203132Written as Doravirine + tenofovir DF + lamivudine
- STARLITE for Unresectable High-Grade GliomasRecruitingPhase 1University of MiamiNCT06428045Written as Lamivudine
- Lamivudine as a Novel Clinical Effort for Rett SyndromeEnrolling by invitationPhase 2Maria Denise Fernandes Carvalho de AndradeNCT07640503Written as Lamivudine
- Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensNot yet recruitingPhase 4Shanghai Public Health Clinical CenterNCT07631897Written as Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
- Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingPhase 2Roswell Park Cancer InstituteNCT04696575Written as Lamivudine
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityRecruitingPhase 3José Antonio Mata MarínNCT07075146Written as DOR/3TC/TDF
- Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpRecruitingPhase 4José Antonio Mata MarínNCT07138144Written as dual therapy
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07031063Written as DTG/3TC
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoRecruitingPhase 4José Antonio Mata MarínNCT06907056Written as dual therapy
- Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTIRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT06602622Written as Doravirine + tenofovir DF + lamivudine
- Antiviral Therapy in Infants With HBV InfectionNot yet recruitingPhase 4Beijing 302 HospitalNCT06503796Written as Lamivudine
- B/F/TAF to DTG/3TC Switch StudyCompletedPhase 3University of NairobiNCT06444620Written as DTG/3TC
- ANRS 12372 MODERATO StudyCompletedPhase 3ANRS, Emerging Infectious DiseasesNCT04022967Written as Lamivudine
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingPhase 3ViiV HealthcareNCT05979311Written as Lamivudine
- Lamivudine for Solid TumorsActive, not recruitingPhase 1/2Thomas MarronNCT06494579Written as Lamivudine
- A Study of Exercise and Pharmacologic Intervention on Systemic InflammationActive, not recruitingPhase 1Icahn School of Medicine at Mount SinaiNCT07058974Written as lamivudine
See all 239 studies that test Lamivudine →
Given beside what is tested · 31 — Lamivudine is usual care or a partner of the new treatment
- Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant PatientsCompletedPhase 4Fundacion Clinic per a la Recerca BiomédicaNCT03360682Written as Lamivudine 300 MG
- A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) InfectionTerminatedPhase 3Janssen Research & Development, LLCNCT03563742Written as Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
- A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsCompletedPhase 2Janssen Sciences Ireland UCNCT00799864Written as Lamivudine
- Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected PatientsCompletedPhase 2Radboud University Medical CenterNCT00943540Written as lamivudine (or emtricitabine)
- Nucleosides And Darunavir/Dolutegravir In AfricaStatus unknownPhase 3Makerere UniversityNCT03988452Written as Lamivudine
- Dosing of Tenofovir and Efavirenz in Antiretroviral TherapyCompletedPhase 4Shanghai Public Health Clinical CenterNCT02945163Written as Lamivudine
- Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug ExposureCompletedPhase 3Babafemi TaiwoNCT02263326Written as lamivudine
- Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical SurgeryStatus unknownPhase 3Fudan UniversityNCT01936233Written as Lamivudine
- Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant WomenCompletedPhase 3University of California, San FranciscoNCT00993031Written as Lamivudine
- A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy RegimenCompletedPhase 2Michael HoelscherNCT01714414Written as 3TC
- SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected WomenCompletedPhase 1St Stephens Aids TrustNCT02499874Written as tenofovir/lamivudine
- Pharmacokinetics of Efavirenz in the Presence of Rifampicin and IsoniazidStatus unknownPhase 1St Stephens Aids TrustNCT02832778Written as tenofovir/lamivudine
- Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIVCompletedPhase 2International Maternal Pediatric Adolescent AIDS Clinical Trials GroupNCT00307151Written as Lamivudine
- A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)CompletedPhase 3Hoffmann-La RocheNCT01095835Written as Lamivudine (LAM)
- Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)TerminatedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00120796Written as Lamivudine
- Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naiveTerminatedPhase 2Bristol-Myers SquibbNCT01489046Written as Lamivudine
- Abacavir and Lamivudine PK in ChildrenCompletedPhase 2/3The HIV Netherlands Australia Thailand Research CollaborationNCT01656122Written as 3TC
- A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis BCompletedPhase 4Hoffmann-La RocheNCT02598063Written as Lamivudine
- Atazanavir and Lamivudine for Treatment SimplificationCompletedPhase 4Catholic University of the Sacred HeartNCT00885482Written as Lamiduvine (Epivir)
- Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedPhase 1/2Gilead SciencesNCT01565889Written as ZDV/3TC
Showing 20 of 31.
As the comparator · 43 — what is tested is compared with Lamivudine
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)RecruitingPhase 2ViiV HealthcareNCT07202546Written as Dolutegravir / Lamivudine (DTG/3TC)
- A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)Not yet recruitingPhase 2ViiV HealthcareNCT07816250Written as DTG/3TC
- Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentRecruitingPhase 3Johns Hopkins UniversityNCT06497465Written as Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Dual therapy: darunavir/cobicistat + lamivudine
- Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedPhase 4Peking Union Medical College HospitalNCT04296695Written as TDF/3TC/EFV
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as Lamivudine
- A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV InfectionCompletedPhase 4Fundacion SEIMC-GESIDANCT04076423Written as Dual Therapy
- A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive AdultsTerminatedPhase 2ViiV HealthcareNCT04900038Written as Lamivudine capsules
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive ParticipantsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT00350272Written as Lamivudine
- Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V MutationCompletedPhase 1/2Alexion Pharmaceuticals, Inc.NCT00312039Written as Lamivudine
- Test Albuvirtide in Experienced PatientsCompletedPhase 3Frontier Biotechnologies Inc.NCT02369965Written as lamivudine
- Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive PatientsStatus unknownPhase 3HeNan Sincere Biotech Co., LtdNCT04303598Written as 3TC
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCompletedPhase 3Gilead SciencesNCT02616783Written as 3TC
- A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM StudyCompletedPhase 4Fundacion SEIMC-GESIDANCT03067285Written as DTG/3TC/ABC + ELV/COBI/FTC/TAF
- Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based RegimenStatus unknownPhase 3Azienda Ospedaliera Universitaria SeneseNCT04155554Written as Dolutegravir/lamivudine/abacavir
- Lamivudine and Adefovir Dipivoxil Fixed Dose CombinationCompletedPhase 1GlaxoSmithKlineNCT01353742Written as Lamivudine
- Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus AdefovirStatus unknownPhase 3Uijeongbu St. Mary HospitalNCT03236584Written as lamivudine plus adefovir combination
- Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus LamivudineCompletedPhase 3Seoul National University HospitalNCT01580202Written as Lamivudine
- TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNACompletedPhase 4Keimyung University Dongsan Medical CenterNCT01732367Written as Lamivudine plus adefovir
- Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B PatientsStatus unknownPhase 4Taipei Veterans General Hospital, TaiwanNCT01491295Written as Lamivudine plus adefovir
Showing 20 of 43.
Codes
What other systems call Lamivudine · ClinicalTrials.gg INT008668
- MeSH (NLM) D019259LamivudineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2T8Q726O95LAMIVUDINEConfirmed FDA, NLM, Wikidata
- RxNorm 68244Confirmed FDA, Wikidata
- Wikidata Q422631lamivudineConfirmed FDA, NLM, Wikidata
- Wikidata Q27266574(+/-)-trans-lamivudineConfirmed NLM, Wikidata
- NCI Thesaurus C1471LamivudineOne source FDA
- DrugBank DB00709One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019259 | Lamivudine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2T8Q726O95 | LAMIVUDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 68244 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422631 | lamivudine | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27266574 | (+/-)-trans-lamivudine | Confirmed NLM, Wikidata |
| NCI Thesaurus | C1471 | Lamivudine | One source FDA |
| DrugBank | DB00709 | — | One source Wikidata |
Also registered as lamivudine, cis(+)- (UNII H6S9D88T3D) and lamivudine, trans(+/-)- (UNII 77ANF82R6X).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.